Amicus Therapeutics (FOLD) Tops Q3 EPS by 10c, updates guidance
Tweet
Share
E-mail
Get Alerts FOLD Hot Sheet
Price: $14.49 --0%
Financial Fact:
Loss from operations: -44.94M
Today's EPS Names:
OFLX, VAXX, NMRD, More
Financial Fact:
Loss from operations: -44.94M
Today's EPS Names:
OFLX, VAXX, NMRD, More
Join SI Premium – FREE
Amicus Therapeutics (NASDAQ: FOLD) reported Q3 EPS of $0.10, $0.10 better than the analyst estimate of $0.00. Revenue for the quarter came in at $141.52 million versus the consensus estimate of $134.93 million.
2024 Financial Guidance:
Total Revenue Growth: 30% to 32%
Galafold Revenue Growth: 16% to 18%
Pombiliti + Opfolda Revenue: $69M to $71M
Non-GAAP Operating Expenses $340M to $350M
For earnings history and earnings-related data on Amicus Therapeutics (FOLD) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Silver Lake In Talks To Buy Workday, Sources Say - Reuters
- Omega Flex (OFLX) Tops Q2 EPS by 27c
- JetBlue promotes Jeffrey Winter to SVP of key operations divisions
Create E-mail Alert Related Categories
EarningsRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
